Evan T. Hall, MD, on Merkel Cell Carcinoma: Tuvusertib With or Without Avelumab

May 31, 2026 By The ASCO Post Staff

Evan T. Hall, MD, of Fred Hutchinson Cancer Center, discusses findings from the randomized phase II MATRiX trial, which evaluated the efficacy of the ATR inhibitor tuvusertib with or without avelumab in patients with anti–PD-(L)1–refractory Merkel cell carcinoma (Abstract LBA9514).

Related Content